Oppenheimer assumed coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report released on Thursday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $12.00 target price on the stock.
OTLK has been the subject of several other reports. ValuEngine raised Outlook Therapeutics from a hold rating to a buy rating in a report on Wednesday, March 20th. Ascendiant Capital Markets initiated coverage on Outlook Therapeutics in a report on Monday, April 22nd. They issued a buy rating and a $4.00 target price for the company.
Shares of OTLK opened at $2.10 on Thursday. Outlook Therapeutics has a 52 week low of $0.85 and a 52 week high of $10.96.
A hedge fund recently bought a new stake in Outlook Therapeutics stock. Renaissance Technologies LLC bought a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,166 shares of the company’s stock, valued at approximately $83,000. Renaissance Technologies LLC owned approximately 0.10% of Outlook Therapeutics as of its most recent SEC filing. Institutional investors own 4.60% of the company’s stock.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Further Reading: How to track put option volume
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.